TABLE 5.

Infusion-related events and laboratory data

Parameter	Value for patients in the following L-AMB dosing group:			P value
	1 mg/kg/day	7.5 mg/kg/wk	15 mg/kg, single dose
Infusion-related events	1	2	2	0.76
Bronchospasm		1
Sternal pain	1
Rigors		1	1
Tachycardia		1
Flushing			1
Mean (SD) laboratory findings
Creatinine concn (mg/dl)
Baseline	0.8 (0.3)	1.0 (0.2)	0.6 (0.15)	0.064
Highest	1.0 (0.3)	1.6 (0.9)	1.6 (1.1)	0.43
Time to maximum Scr level (days)	11.2 (4.3)	4.3 (1.9)	3 (1.3)	0.0002
Scr level (mg/dl) at end of therapy	0.9 (0.4)	0.9 (0.3)	1.0 (0.4)	0.83
No. of patients with nephrotoxicitya	1	1	3	0.43
Mean (SD) day of nephrotoxicity	16	3	4 (0.6)	0.003
Potassium concn (meq/liter)
Baseline	4.1 (0.4)	3.9 (0.4)	3.8 (0.4)	0.76
End of therapy	3.3 (0.3)	3.0 (0.1)	4.3 (0.6)	0.47
No. of patients with hypokalemia	1	1	3	0.44
Magnesium concn (mg/dl)
Baseline	1.8 (0.1)	1.9 (0.2)	1.8 (0.5)	0.82
End of therapy	1.8 (0.4)	1.1 (0.6)	1.7 (0.2)	0.16
No. of patients with hypomagnesemia	5	4	6	0.41
Phosphorus concn (mg/dl)
Baseline	3.0 (0.5)	3.4 (0.9)	3.2 (0.5)	0.64
End of therapy	3.1 (0.8)	3.0 (0.4)	3.8 (1.5)	0.13
No. of patients with hypophosphatemia	6	3	5	0.46
AST concn (IU/liter)
Baseline	17.0 (1.4)	19.0 (4.2)	28.3 (28.6)	0.88
End of therapy	15.0 (7.8)	18.5 (10.6)	20.3 (4.6)	0.61
ALT concn (IU/liter)
Baseline	17.5 (3.5)	24 (4.2)	33.0 (30.3)	0.58
End of therapy	25.8 (15.0)	27.5 (9.2)	18.3 (10.0)	0.72
Alkaline phosphatase concn (IU/liter)
Baseline	61.5 (6.4)	35.5 (14.8)	53.7 (15.9)	0.11
End of therapy	88.0 (31.8)	115 (52.3)	68.3 (35.8)	0.90
Total bilirubin level (mg/dl)
Baseline	0.6 (0.3)	1.1 (0.4)	0.9 (0.2)	0.33
End of therapy	0.6 (0.4)	0.7 (0.5)	0.9 (0.1)	0.11